嵌合抗原受体T细胞治疗淋巴瘤研究进展

Updates in chimeric antigen receptor T-cell therapy for lymphoma

近年来，嵌合抗原受体T细胞（CAR—T细胞）在血液系统肿瘤的治疗中取得很多成绩，尤其在白血病和淋巴瘤治疗中的数据引人瞩目。由于一些重要数据的出现，2017年美国医疗市场有望迎来第一个细胞产品。文章报道了58届美国血液学会（ASH）年会上报道的CAR—T细胞在淋巴瘤治疗领域的一些关键数据。

Tremendous success has emerged in chimeric antigen receptor （CAR）-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.